It is also possible that S6K1 disruption is inducing changes in the signaling network through its regulation of the insulin/IGF-1 signaling network (Johnson et al., 2013a) or additional targets, or that S6K1 disruption is alleviating mitochondrial disease in these animals by a mechanism distinct from rapamycin. The gene discussed is RPS6KB1; the disease is mitochondrial disease.